Laforin

EPM2A
Identifiers
AliasesEPM2A, EPM2, MELF, epilepsy, progressive myoclonus type 2A, Lafora disease (laforin), laforin glucan phosphatase, EPM2A glucan phosphatase, laforin
External IDsOMIM: 607566; MGI: 1341085; GeneCards: EPM2A
Available structures
PDBOrtholog search: PDBe RCSB
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
3.1.3.16↗↗↗↗
3.1.3.48↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

7957

13853

Ensembl

ENSG00000112425

ENSMUSG00000055493

UniProt

O95278

Q9WUA5

RefSeq (mRNA)

NM_010146

RefSeq (protein)

NP_034276

Location (UCSC)Chr 6: 145.38 – 145.74 MbChr 10: 11.22 – 11.34 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse
epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)
Identifiers
SymbolEPM2A
NCBI gene7957
HGNC3413
OMIM607566
PDB4RKK
RefSeqNM_001018041
UniProtO95278
Other data
LocusChr. 6 q24
Search for
StructuresSwiss-model
DomainsInterPro

Laforin, encoded by the EPM2A gene, is a phosphatase, with a carbohydrate-binding domain, which is mutated in patients with Lafora disease. It contains a dual specificity phosphatase domain (DSP) and a carbohydrate binding module subtype 20 (CBM20). Its physiological substrate has yet to be identified and the molecular mechanisms in which mutated laforin causes Lafora disease is unknown, though there has been progress made in the study by Ortolano et al. Laforin regulates autophagy via Mammalian target of rapamycin, which is impaired in Lafora disease.